中国神经再生研究(英文版) ›› 2025, Vol. 20 ›› Issue (6): 1715-1716.doi: 10.4103/NRR.NRR-D-24-00209

• 观点:神经损伤修复保护与再生 • 上一篇    下一篇

利用诱导多能干细胞衍生的内皮细胞对中枢神经系统髓鞘再形成的治疗潜力

  

  • 出版日期:2025-06-15 发布日期:2024-11-12

Harnessing therapeutic potential of induced pluripotent stem cell– derived endothelial cells for remyelination in the central nervous system

Dan Ma* , Nona Pop   

  1. Aston Medical School, College of Health and Life Sciences, Aston University, Birmingham, UK
  • Online:2025-06-15 Published:2024-11-12
  • Contact: Dan Ma, PhD, d.ma@aston.ac.uk.
  • Supported by:
    This work was supported by a grant from Aston University, Birmingham, UK (to DM).

摘要: https://orcid.org/0000-0001-8628-8954 (Dan Ma)

Abstract: Myelin is the protective sheath surrounding nerve fibers, and its damage (demyelination) occurs in many central nervous system (CNS) diseases, including multiple sclerosis (MS), traumatic injury, neurodegenerative diseases such as Alzheimer’s disease, and mental disorders such as schizophrenia (Barateiro et al., 2016). Repair of damaged myelin sheaths (remyelination) often fails in MS, leading to neuronal loss and irreversible functional deficits. Remyelination involves the activation and recruitment of adult oligodendrocyte progenitor cells (OPCs), the residential stem cells in CNS, which eventually differentiate into new mature oligodendrocytes and form new myelin sheaths on demyelinated axons. Promoting remyelination emerges as a potentially effective clinical intervention for a broad range of demyelinating diseases such as progressive MS (Franklin and Ffrench-Constant, 2017). Currently, there is no treatment directly promoting remyelination in the clinic.